8-K - MBOT - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

of

the Securities Exchange Act of 1934

Dateof Report (Date of earliest event reported): September 17, 2025

MICROBOT

MEDICAL INC.

(Exactname of registrant as specified in its charter)

Delaware	000-19871	94-3078125
(State or other jurisdiction<br><br> <br>of incorporation)	(Commission<br><br> <br>File Number)	(IRS Employer<br><br> <br>Identification No.)

175Derby St., Bld. 27

Hingham,MA 02043

(Addressof Principal Executive Offices) (Zip Code)

Registrant’stelephone number, including area code: (781) 875-3605

(FormerName or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications<br> pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant<br> to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications<br> pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications<br> pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par<br> value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements ofCertain Officers.

On September 17, 2025, Microbot Medical Inc. (the “Company”) granted special one-time cash bonuses to certain of its executive officers, as follows:

●	Harel<br> Gadot, the Company’s CEO, President and Chairman, received $158,115;
●	Simon<br> Sharon, the Company’s CTO, received approximately $64,200; and
●	Rachel<br> Vaknin, the Company’s CEO, received approximately $32,500.

In making the determination to grant such bonuses, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) considered in part that each of the executives waived between 30-50% of their prorated annual base salary in part of 2023, as part of the Company’s May 2023 cost restructuring plan.

In addition, the Compensation Committee approved an amendment to the Company’s compensation package for the non-management members of its Board of Directors (the “Board”), and authorized one-time cash payments to each of the Company’s non-management members of the Board of between $30,000 and $45,000.

(d) Exhibits.

Exhibit<br> No.	Description
104	Cover Page Interactive<br> Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.
By:	/s/ Harel Gadot
Name:	Harel Gadot
Title:	Chief Executive Officer, President and<br> Chairman

Date: September 19, 2025